---
title: "Chandan Healthcare Ltd (CHANDAN) — Share Price, Financials & Analysis"
symbol: "CHANDAN"
company: "Chandan Healthcare Ltd"
canonical: "https://tapetide.com/stocks/CHANDAN"
isin: "INE0B2N01016"
nse_symbol: "CHANDAN"
sector: "Healthcare Services"
industry: "Healthcare Service Provider"
market_cap_cr: 496.62
generated_at: "2026-09-13T18:50:54.772Z"
---

# Chandan Healthcare Ltd (CHANDAN)

Canonical page: https://tapetide.com/stocks/CHANDAN

## Company

- **NSE Symbol:** CHANDAN
- **ISIN:** INE0B2N01016
- **Sector:** Healthcare Services
- **Industry:** Healthcare Service Provider
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-02-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** chandandiagnostic.com

## About

Incorporated in September 2003, Chandan Healthcare Limited runs diagnostic centers in North India with pathology and radiology testing services.[1]

## Latest Price

- **Price:** ₹199.8
- **Change:** -3.4 (-1.67%)
- **Open:** ₹202
- **Day High:** ₹205.95
- **Day Low:** ₹198.6
- **Previous Close:** ₹203.2
- **Volume:** 40000
- **As Of:** 2026-09-11T09:58:55+00:00

## Key Fundamentals

Observed at 2026-09-11T04:42:01.432658Z.

- **Market Cap:** ₹496.62 Cr
- **Classification:** SME
- **P/E (reported):** 19.7
- **P/E (TTM):** 19.74
- **EPS (TTM):** ₹10.12
- **Book Value:** ₹69.48
- **Price to Book:** 2.92
- **Dividend Yield:** 0%
- **ROE:** 18.6%
- **ROCE:** 23.83%
- **Debt to Equity:** 0.32
- **Revenue (yearly):** ₹276.39 Cr
- **Net Income:** ₹28.93 Cr
- **EBITDA:** ₹49.65 Cr
- **52-Week High:** ₹358
- **52-Week Low:** ₹185.4
- **RSI (14):** 34.63

## Tapetide Score

- **Score:** 47 / 100
- **Score date:** 2026-09-04
- **Archetype:** Weak and Under Pressure
- **What it means:** Weak financials are the defining feature, and neither the valuation nor the trend reading is strong enough to offset them. Worth reading the risk flags and recent filings closely before anything else.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Falling
- **Percentile:** 35.6 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 41.25 | 9% |
| growth | 70.42 | 9% |
| momentum | 17.72 | 12% |
| ownership | 53.8 | 24% |
| quality | 41.9 | 22% |
| valuation | 53.67 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 82.4 to 114 days.
- Working capital days have increased from 61.8 days to 111 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | — | -745.56% | — |
| ebitda margin growth | 57.89% | -5.35% | 13.91% | 715.21% |
| net income growth | 61.22% | 23.11% | 79% | — |
| revenue growth | 6.33% | 19.03% | 26% | 18.18% |
| roce | 72.26% | -40.71% | 33.2% | 19.02% |
| roe | 60.12% | -50.39% | 22.67% | 402.7% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 54.64 | 62.65 | 67.9 | 67.9 | 65.01 | 75.58 | 80.85 |
| Expenses | 45.75 | 52.41 | 54.03 | 53.75 | 53.17 | 64.1 | 61.27 |
| Operating Profit | 8.89 | 10.24 | 13.87 | 14.15 | 11.84 | 11.48 | 19.58 |
| OPM % | 16.27 | 16.34 | 20.43 | 20.84 | 18.21 | 15.19 | 24.22 |
| Other Income | 0.17 | 2.42 | 0.87 | 0.84 | -1.46 | 1.85 | 1.41 |
| Interest | 1.09 | 1.3 | 1.37 | 1.4 | 1.28 | 1.78 | 4.83 |
| Depreciation | 1.35 | 2.7 | 3.75 | 2.46 | 2.4 | 3.74 | 4.47 |
| Profit before tax | 6.62 | 8.66 | 9.62 | 11.13 | 6.7 | 7.81 | 11.69 |
| Tax % | 30.21 | 29.56 | 35.65 | 25.79 | 24.93 | 36.62 | 32.34 |
| Net Profit | 4.2 | 6.02 | 6.19 | 7.8 | 4.54 | 4.94 | 7.92 |
| EPS in Rs | 2.1 | 2.46 | 2.37 | 3.19 | 1.86 | 2 | 3.07 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 120 | 137 | 177 | 230 | 276 | 289 |
| Expenses | 117 | 128 | 150 | 189 | 219 | 232 |
| Operating Profit | 2 | 9 | 26 | 41 | 57 | 57 |
| OPM % | 1.9 | 7 | 15 | 18 | 21 | 20 |
| Other Income | 0 | 0 | 1 | 2 | 4 | 3 |
| Interest | 2 | 2 | 3 | 5 | 14 | 9 |
| Depreciation | 2 | 2 | 3 | 7 | 15 | 13 |
| Profit before tax | -1 | 5 | 21 | 32 | 32 | 37 |
| Tax % | 3 | 28 | 24 | 27 | 37 | — |
| Net Profit | -1 | 3 | 16 | 24 | 20 | 25 |
| EPS in Rs | -0.56 | 1.68 | 8.14 | 9.07 | 7.93 | 10.12 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 20 | 20 | 20 | 24 | 24 |
| Reserves | 4 | 7 | 21 | 98 | 147 |
| Borrowings | 17 | 21 | 36 | 48 | 54 |
| Other Liabilities | 41 | 49 | 41 | 40 | 65 |
| Total Liabilities | 82 | 98 | 118 | 211 | 290 |
| Fixed Assets | 29 | 33 | 48 | 76 | 101 |
| CWIP | 0 | 0 | 0 | 4 | 12 |
| Investments | 6 | 7 | 3 | 1 | 20 |
| Other Assets | 46 | 58 | 66 | 129 | 156 |
| Total Assets | 82 | 98 | 118 | 211 | 290 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 6 | 4 | 1 | -29 | 16 |
| Cash from Investing Activity | -11 | -6 | -15 | -36 | -40 |
| Cash from Financing Activity | 3 | 2 | 16 | 67 | 21 |
| Net Cash Flow | -1 | 0 | 2 | 2 | -3 |
| Free Cash Flow | -1 | -1 | -18 | -68 | -26 |
| CFO/OP | 275 | 60 | 23 | -50 | 45 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 88 | 63 | 59 | 74 | 114 |
| Inventory Days | 46 | 71 | 96 | 126 | 92 |
| Days Payable | 185 | 251 | 102 | 102 | 112 |
| Cash Conversion Cycle | -51 | -117 | 53 | 98 | 95 |
| Working Capital Days | -11 | -21 | -1 | 75 | 111 |
| ROCE % | — | 16 | 37 | 29 | 23 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 69.93% | 49.43% | 49.47% | 49.47% | 49.55% | 49.61% |
| FIIs | 0% | 3.86% | 1.11% | 0% | 0.01% | 0.01% |
| DIIs | 0% | 0% | 0% | 4.76% | 5.03% | 5.09% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 0% | 33% | 37.07% | 39.93% | 39.5% | 39.1% |
| Others | 30.07% | 13.7% | 12.35% | 5.84% | 5.92% | 6.19% |
| No. of Shareholders | 59 | 897 | 1307 | 1464 | 1624 | 1591 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 4 / 3 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 211.94 | Sell |
| EMA (10) | 211.51 | Sell |
| SMA (20) | 221.54 | Sell |
| EMA (20) | 218.71 | Sell |
| SMA (50) | 233.09 | Sell |
| EMA (50) | 228.87 | Sell |
| SMA (100) | 237.12 | Sell |
| EMA (100) | 237.37 | Sell |
| SMA (200) | 258.16 | Sell |
| EMA (200) | 241.41 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 32.97 | Neutral |
| MACD (12,26,9) | -8.52 | Sell |
| Stochastic (14,3,3) | 10.14 | Buy |
| ADX (14) | 31.66 | Buy |
| Williams %R (14) | -96.38 | Buy |
| ATR (14) | 9.6 | High Volatility |
| ROC (12) | -11.69 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 45.81 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 Sep - Newspaper advertisement published for 23rd AGM notice and e-voting instructions on 09 September 2026. | [Copy of Newspaper Publication 9 Sep - Newspaper advertisement published for 23rd AGM notice and e-voting instructions on 09 September 2026.](https://nsearchives.nseindia.com/corporate/CHANDAN_09092026120855_NSE_Disclosure.pdf) |
| 8 July 2026 - Revised audited results for FY26 and H1 ended March 31, 2026 filed; NSE clarification and no fund deviation. | [Reply to Clarification- Financial results 8 July 2026 - Revised audited results for FY26 and H1 ended March 31, 2026 filed; NSE clarification and no fund deviation.](https://nsearchives.nseindia.com/corporate/CHANDAN_29062026123013_NSE_Rev-Financials_2025-26-_-_Copy.pdf) |
| 7 Sep - Submitted FY2025-26 annual report and AGM notice; 23rd AGM on 30 September 2026 at 4:00 PM via VC. | [Shareholders meeting 7 Sep - Submitted FY2025-26 annual report and AGM notice; 23rd AGM on 30 September 2026 at 4:00 PM via VC.](https://nsearchives.nseindia.com/corporate/CHANDAN_07092026183249_NSE_Disclosure_of_Notice_and_AR.pdf) |
| 7 Sep - Investor/analyst group meeting scheduled virtually on September 11, 2026 at 1:00 P.M. IST. | [Analysts/Institutional Investor Meet/Con. Call Updates 7 Sep - Investor/analyst group meeting scheduled virtually on September 11, 2026 at 1:00 P.M. IST.](https://nsearchives.nseindia.com/corporate/CHANDAN_07092026153732_Intimation-Investors_meet.pdf) |
| 7 Sep - Board recommended appointing Sanjay Srivastava as independent director and reallocated ₹50 crore warrant proceeds for new diagnostic centres. | [Outcome of Board Meeting 7 Sep - Board recommended appointing Sanjay Srivastava as independent director and reallocated ₹50 crore warrant proceeds for new diagnostic centres.](https://nsearchives.nseindia.com/corporate/CHANDAN_07092026164113_Outcome_of_Board_Meeting_07Sep2026_NSE_Filing.pdf) |
| 7 Aug - Entire 53.56% stake in Chandan Pharmacy sold to Chandan Hospital for Rs 31.31 crore; subsidiary ceases. | [General Updates 7 Aug - Entire 53.56% stake in Chandan Pharmacy sold to Chandan Hospital for Rs 31.31 crore; subsidiary ceases.](https://nsearchives.nseindia.com/corporate/CHANDAN_07082026154128_Shareholder_Statement_CPL_Divestment-.pdf) |
| 7 Aug - EGM on Aug 29, 2026 to approve sale of 53.56% stake in Chandan Pharmacy for Rs16.77 crore. | [Shareholders meeting 7 Aug - EGM on Aug 29, 2026 to approve sale of 53.56% stake in Chandan Pharmacy for Rs16.77 crore.](https://nsearchives.nseindia.com/corporate/CHANDAN_07082026103929_Notice_of_EGM-.pdf) |
| 7 Aug - Board approved sale of 53.56% stake in Chandan Pharmacy Ltd for Rs 31.31 crore on Aug. 6, 2026. | [General Updates 7 Aug - Board approved sale of 53.56% stake in Chandan Pharmacy Ltd for Rs 31.31 crore on Aug. 6, 2026.](https://nsearchives.nseindia.com/corporate/CHANDAN_07082026152450_Shareholder_Statement_CPL_Divestment.pdf) |
| 7 Aug - Board approved sale of 53.56% stake in Chandan Pharmacy for Rs 31.31 crore; subsidiary ceases. | [General Updates 7 Aug - Board approved sale of 53.56% stake in Chandan Pharmacy for Rs 31.31 crore; subsidiary ceases.](https://nsearchives.nseindia.com/corporate/CHANDAN_07082026191437_Shareholder_Statement_CPL_Divestment.pdf) |
| 6 March 2026 - Commenced diagnostic operations in Kurukshetra, Haryana with Jeena Sikho; exclusive five-year partnership; March 6, 2026. | [General Updates 6 March 2026 - Commenced diagnostic operations in Kurukshetra, Haryana with Jeena Sikho; exclusive five-year partnership; March 6, 2026.](https://nsearchives.nseindia.com/corporate/CHANDAN_06032026113319_Disclosure_NSE.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/CHANDAN_17112025103543_Investor_Presentation_H1_2025-26.pdf) |
| Feb 2026 | [Concall - Feb 2026](https://nsearchives.nseindia.com/corporate/CHANDAN_18022026181030_Transcript_Q3_NSE.pdf) |
| Dec 2025 | [Concall - Dec 2025](https://nsearchives.nseindia.com/corporate/CHANDAN_20112025161820_CHCL_H1_FY26_Concall_Transcript.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://nsearchives.nseindia.com/corporate/CHANDAN_25082025181216_Regulation_30-Presentation_24-08-2025.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_31746_CHANDAN_2025_2026_A_14296788_07092026182954.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28888_CHANDAN_2024_2025_A_4544654_08092025122118.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/353e400f-acac-4a36-9853-fae18ab6dcf5.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1648479e-ada3-4ec6-bd7e-5a50904b8f5c.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/74733517399.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/70516517399.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/67570517399.pdf) |
| from bse | [Financial Year 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/5173990319.pdf) |
| from bse | [Financial Year 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/5173990318.pdf) |
| from bse | [Financial Year 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/517399/5173990317.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:50:54.772Z.